The use of radioactive iodine (131 I) for the treatment of thyroid carcinoma has changed over
the past 50 y. These changes are based on increasing awareness of the biophysical …

This article discusses several aspects of the evaluation and management of differentiated
thyroid carcinoma that are changing or may change in the near future. Although …

Radioiodine (131 I) treatment of well-differentiated thyroid carcinoma is a well-evaluated
therapeutic model for nuclear medicine which has never been equaled by subsequent …

Nuclear Medicine Service and Medical Service, Hines Veterans Affairs Hospital, Hines,
Illinois; and Division of Nuclear Medicine, Department ofRadiology, and Department …

Post-surgical ablative iodine-131 therapy is recommended for all differentiated thyroid
cancer primary tumors> 1cm in diameter. Regarding smaller primary tumors, 131I ablation …

There is an abundance of evidence indicating that the oral administration of sodium 13II-
iodide is of value in the management of well-differentiated thyroid cancers. The first step in …

Thyroid cancer is a rare malignancy with wide interethnic and geographic variations. In
Germany thyroid carcinoma is the 13th most frequent malignancy (2.7 new cases yearly per …

Radioiodine-131 has attained a significant role in the treatment of differentiated thyroid
cancer. The most favorable outcome can be expected when iodine-131 is used in …

For almost five decades, 131I treatment of thyroid cancer has been based empirically on
administered activity rather than on actual radiation doses delivered. In 1983, we defined …

There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …